BIO 2021 Notebook: A Breakthrough Year For Emerging Companies?

 
• By Pink Sheet Team and Scrip Team

News and views from day two of the BIO Digital annual meeting include the increasing number of small companies driving US product approvals, an update on the Reagan-Udall RWE Accelerator project and Merck & Co.'s Julie Gerberding on the need for continued HIV/AIDS research.

BIO 2021 Notebook - Day 2
BIO included updates on the Reagan-Udall RWE accelerator project and the need to put digital product data into context for stakeholders.

More from US FDA Performance Tracker

More from Regulatory Trackers